BlossomHill Therapeutics
BLSM
16.61
-0.68
-3.93%
BlossomHill Therapeutics
US · BLSM
#3711 by market cap
Listed 2026
16.61
-0.68
-3.93%
Live - 5344 symbols - heartbeat 269s ago
· 2026-10-08 04:52
Pre-market
16.34
-1.63%
After-hours
16.06
-3.31%
- Market cap
- 527.95M
- P/E (TTM)i
- -6.80
- P/Bi
- -3.02
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 11%
Reader sentiment
Are you bullish or bearish on BLSM?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 4.59M | 7.89M |
| Research & development | 31.81M | 56.14M |
| Operating profit | -36.40M | -64.02M |
| Pretax profit | -30.70M | -60.56M |
| Tax | -- | -- |
| Net profit | -30.70M | -60.56M |
| Basic EPS | -1 | -4 |
| Diluted EPS | -1.47 | -3.69 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 1.88M | 1.57M | 2.21M | 3.32M |
| Research & development | 9.57M | 12.53M | 19.90M | 21.36M |
| Operating profit | -11.45M | -14.10M | -22.11M | -24.67M |
| Pretax profit | -10.48M | -13.24M | -21.01M | -23.76M |
| Tax | -- | -- | -- | -- |
| Net profit | -10.48M | -13.24M | -21.01M | -23.76M |
| Basic EPS | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.50 | -0.64 | -1.01 | -0.78 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 104.17M | 138.83M |
| Cash & ST investments | 100.15M | 136.68M |
| Inventory | -- | -- |
| Total assets | 106.78M | 162.97M |
| Total current liabilities | 6.77M | 15.48M |
| Short-term debt | 525.00K | 5.00K |
| Long-term debt | -- | -- |
| Total liabilities | 179,658,000.00 | 294,696,000.00 |
| Total equity | -72.88M | -131.73M |
| Retained earnings | -74.47M | -135.03M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 119.72M | 100.97M |
| Cash & ST investments | -- | -- | 116.00M | 95.38M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 143.41M | 124.13M |
| Total current liabilities | -- | -- | 16.18M | 18.62M |
| Short-term debt | -- | -- | 493.00K | 1.15M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 295,530,000.00 | 298,911,000.00 |
| Total equity | -- | -- | -152.12M | -174.78M |
| Retained earnings | -- | -- | -156.04M | -179.80M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -31.42M | -46.93M |
| Depreciation & amortization | 350.00K | 441.00K |
| Free cash flow | -31.51M | -47.99M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 100.15M | 136.68M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -10.98M | -9.14M | -20.94M | -23.23M |
| Depreciation & amortization | 85.00K | 102.00K | 125.00K | 125.00K |
| Free cash flow | -11.38M | -9.74M | -20.95M | -23.23M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 88.81M | 79.11M | 116.00M | 95.38M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -28.75 | -44.90 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 15.38 | 8.97 |
| Quick ratioi | 14.79 | 8.83 |
| Debt / assetsi | 0.49 | 13.74 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -- | -- | -49.57 | -65.74 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 7.40 | 5.42 |
| Quick ratioi | -- | -- | 7.17 | 5.12 |
| Debt / assetsi | -- | -- | 16.05 | 18.83 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 04:52:37 · For reference only, not investment advice and not tailored to your situation.